NCT00310804 - Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60) | Biotech Hunter

Enrollment

1,200

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

October 31, 2005

Study Completion Date

April 30, 2006

Conditions

Influenza

Interventions

BIOLOGICAL

Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)

One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1

BIOLOGICAL

Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)

One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2

BIOLOGICAL

Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)

One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3

BIOLOGICAL

Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)

One single 0.5ml intramuscular injection of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).

Trial Locations (2)

2nd Department of Internal Diseases, Panevezys Hospital,, Panevezys

Dept. Infectious Diseases and Microbiology of Vilnius University, Vilnius